---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-009432"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T16:53:39.985730+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO

## Summary
- First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.
- Oxford loan settlement: $2M cash and 1.62M common shares reduce loan by $7M; $1M initial cash due by Jan 15, 2026 or stockholder meeting.
- David Lazar appointed CEO and board chair; Mary Reumuth terminated as CFO; Gregory Perry resigns from board.
- Company terminated all remaining employees in October after Oxford foreclosure; now resumes operations with limited cash from placement.
- Stockholder meeting required before March 31, 2026 to approve share increase and conversion of preferred shares.

## SEC filing metadata
- accession: 0001829126-25-009432
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 5.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000182912625009432/0001829126-25-009432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000182912625009432/kalabio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-009432
- JSON: https://secwatch.observer/filing/0001829126-25-009432.json
- Plain text: https://secwatch.observer/filing/0001829126-25-009432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.